| Sentence | Sentiment | Title | Url | Date |
|---|
| An editorial in the influential New England Journal of Medicine cites problems with a World Health Organization study that found Gilead Sciences Incs antiviral remdesivir failed to improve COVID19 survival and said it does not refute trials that demonstrated benefits of the drug in treating the illness | Negative | An editorial in the influential New England Journal of Medicine cites problems with a World Health Organization study that found Gilead Sciences Incs antiviral remdesivir failed to improve COVID19 survival and said it does not refute trials that demonstrated benefits of the drug in treating the illness | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/medical-journal-editorial-refutes-who-finding-on-gileads-remdesivir-for-covid-19-idUSKBN28C3EZ | 2020-12-03 |
| Veklury is recognised as a standard of care for the treatment of hospitalised patients with COVID19 in guidelines from numerous credible national Gilead said in a statement | Positive | LONDON Gileads remdesivir is not recommended for patients hospitalised with COVID19 regardless of how ill they are as there is no evidence the drug improves survival or reduces the need for ventilation a World Health Organization panel said on Friday | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir-who/who-advises-against-gileads-remdesivir-for-all-hospitalised-covid-19-patients-idUSKBN28000Q | 2020-11-20 |
| GENEVA The World Health Organization said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID19 treatments after the trial found Gilead Sciences remdesivir had no impact on survival rates | Negative | GENEVA The World Health Organization said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID19 treatments after the trial found Gilead Sciences remdesivir had no impact on survival rates | http://www.reuters.com/places/africa/article/us-health-coronavirus-who-trials/who-trial-to-assess-other-antibody-antiviral-drugs-after-remdesivir-doubt-idUSKBN2712HV | 2020-10-17 |
| LONDON When it comes to trials of any drug size matters potentially giving the World Health Organizations gloomy verdict on Gilead Sciences COVID19 treatment remdesivir an edge over the companys more positive data leading scientists say | Neutral | LONDON When it comes to trials of any drug size matters potentially giving the World Health Organizations gloomy verdict on Gilead Sciences COVID19 treatment remdesivir an edge over the companys more positive data leading scientists say | http://www.reuters.com/subjects/euro-zone/article/us-health-coronavirus-remdesivir-trials/gloomy-covid-drug-data-shows-why-big-randomised-trials-matter-idUSKBN2712FS | 2020-10-17 |
| The trial will test the hyperimmune globulin therapy in combination with Gilead Sciences Incs antiviral drug remdesivir compared with patients who get remdesivir alone he said | Negative | NEW YORK The Takeda Pharmaceutical Coled group that is developing a blood plasma treatment for COVID19 has started manufacturing while the latestage trial to determine whether it works is ongoing Takeda Chief Executive Christophe Weber said on Monday | http://www.reuters.com/news/health/article/us-health-coronavirus-takeda/takeda-group-begins-manufacturing-covid-19-plasma-treatment-ahead-of-approval-idUSKBN26X2MW | 2020-10-13 |
| Patients will be treated with Gilead Science Incs Remdesivir alongside the plasma treatment which will be provided by CSL Behring Takeda and two other companies | Positive | TOKYO Japans Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID19 after months of regulatory delays | http://www.reuters.com/places/japan/article/us-health-coronavirus-takeda-plasma/takeda-led-covid-19-plasma-treatment-enters-clinical-trial-with-first-patient-idUSKBN26U020 | 2020-10-09 |
| The U.S. Department of Health and Human Services said on Thursday that U.S. hospitals can now buy Gilead Sciences Incs antiviral COVID19 drug remdesivir from the company and its distributor | Negative | The U.S. Department of Health and Human Services said on Thursday that U.S. hospitals can now buy Gilead Sciences Incs antiviral COVID19 drug remdesivir from the company and its distributor | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-hhs/hhs-says-gilead-distributor-can-directly-sell-covid-19-drug-in-u-s-idUSKBN26M791 | 2020-10-02 |
| Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | Positive | Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | http://www.reuters.com/finance/article/us-immunomedics-m-a-gilead-sciences/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-wsj-reports-idUSKBN2630ZL | 2020-09-13 |
| An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio | Positive | Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than billion in a deal that would further expand Gileads portfolio of cancer treatments the Wall Street Journal reported on Saturday | http://www.reuters.com/finance/article/us-immunomedics-m-a-gilead-sciences/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-wsj-reports-idUSKBN2630ZL | 2020-09-13 |
| As evidence grew this spring that the drug remdesivir was helping COVID19 patients some Wall Street investors bet on analysts estimates that its maker Gilead Sciences Inc could charge up to for the treatment | Neutral | As evidence grew this spring that the drug remdesivir was helping COVID19 patients some Wall Street investors bet on analysts estimates that its maker Gilead Sciences Inc could charge up to for the treatment | http://www.reuters.com/finance/article/us-usa-drugpricing-lobbying-special-repo/special-report-big-pharma-wages-stealth-war-on-drug-price-watchdog-idUSKBN2621IQ | 2020-09-12 |
| The U.S. government has allocated more than 11000 courses of Gilead Sciences Incs COVID19 treatment remdesivir to the four states now being hardest hit by the fastspreading outbreak in the United States | Negative | The U.S. government has allocated more than 11000 courses of Gilead Sciences Incs COVID19 treatment remdesivir to the four states now being hardest hit by the fastspreading outbreak in the United States | http://www.reuters.com/news/health/article/us-health-coronavirus-usa-remdesivir/hhs-allocates-gileads-covid-19-drug-remdesivir-to-four-hardest-hit-states-idUSKBN24B2Z3 | 2020-07-11 |
| Concerns over remdesivirs availability were ignited after Gilead pledged almost all its output to the United States | Negative | The source who declined to be identified because of the sensitivity of the topic did not disclose the terms of the deals | http://www.reuters.com/news/health/article/us-health-coronavirus-eu-treatments-excl/exclusive-eu-secures-potential-covid-19-drugs-from-roche-germanys-merck-idUSKBN2491EC | 2020-07-09 |
| We trust Gilead will meet this it said | Positive | Some governments in Europe and Asia said on Wednesday they have enough of Gileads COVID19 antiviral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/world-takes-stock-of-covid-19-drug-remdesivir-after-u-s-snaps-up-supplies-idUSKBN2426ZG | 2020-07-02 |
| Some governments in Europe and Asia said on Wednesday they have enough of Gileads COVID19 antiviral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months | Positive | Some governments in Europe and Asia said on Wednesday they have enough of Gileads COVID19 antiviral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/world-takes-stock-of-covid-19-drug-remdesivir-after-u-s-snaps-up-supplies-idUSKBN2426ZG | 2020-07-02 |
| It will be down to manufacturers Gilead to boost production in order to satisfy demand for the use of remdesivir | Positive | Some governments in Europe and Asia said on Wednesday they have enough of Gileads COVID19 antiviral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-remdesivir/world-takes-stock-of-covid-19-drug-remdesivir-after-u-s-snaps-up-supplies-idUSKBN2426ZG | 2020-07-02 |
| SEOUL South Korea has started distributing stocks of the COVID19 treatment remdesivir which have been donated by Gilead Sciences Inc and plans to begin talks to purchase more supplies in August its disease control agency said | Positive | SEOUL South Korea has started distributing stocks of the COVID19 treatment remdesivir which have been donated by Gilead Sciences Inc and plans to begin talks to purchase more supplies in August its disease control agency said | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-remdesi/south-korea-says-to-begin-talks-to-purchase-covid-19-drug-remdesivir-in-august-idUSKBN2423WI | 2020-07-01 |
| Experts have said Gilead would need to avoid appearing to take advantage of a health crisis for profits | Negative | Gilead Sciences Inc on Monday priced its COVID19 antiviral remdesivir at per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-sciences/gilead-prices-covid-19-drug-remdesivir-at-2340-per-patient-in-developed-nations-idUSKBN2401C8 | 2020-06-30 |
| The European healthcare regulators endorsement put Gileads antiviral drug remdesivir on track to become the first therapy for the disease on the continent | Negative | Government experts believe more than 20 million Americans could have contracted the coronavirus 10 times more than official counts indicating many people without symptoms have or have had the disease senior administration officials said | http://www.reuters.com/subjects/middle-east/article/us-health-coronavirus-latest-factbox/factbox-latest-on-the-worldwide-spread-of-the-coronavirus-idUSKBN23V399 | 2020-06-26 |
| This is the third deal by Gilead in the span of four months aimed at expanding its oncology portfolio Jefferies analyst Michael Yee said in a client note | Positive | Gilead Sciences Inc said on Tuesday it would buy a 49 | http://www.reuters.com/finance/deals/article/us-pionyr-m-a-gilead-sciences/gilead-to-buy-49-9-stake-in-cancer-drug-developer-for-275-million-idUSKBN23U1ZR | 2020-06-24 |
| This is the most rational way to create longterm value rather than one big acquisition and sets up Gilead for lots of interesting data in Yee said | Positive | Gilead Sciences Inc said on Tuesday it would buy a 49 | http://www.reuters.com/finance/deals/article/us-pionyr-m-a-gilead-sciences/gilead-to-buy-49-9-stake-in-cancer-drug-developer-for-275-million-idUSKBN23U1ZR | 2020-06-24 |
| after Bloomberg reported it had approached U.S. rival Gilead Sciences about a possible merger to form one the worlds largest drug companies | Positive | a live blog on European stocks type in an Eikon news | http://www.reuters.com/finance/markets/article/europe-stocks/european-shares-pull-back-from-3-month-highs-after-rally-idUSL4N2DL1F8 | 2020-06-09 |
| We think Gilead believes its HIV business is very they said in a note adding that the company would prefer to build value over time and do its own tuckin | Positive | A spokeswoman for AstraZeneca said the company does not comment on rumours or speculation | http://www.reuters.com/finance/article/us-gilead-sciences-m-a-astrazeneca/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-idUSKBN23E09O | 2020-06-08 |
| It also plans to test if mixing antiinflammation drug Actemra with Gilead Sciences Incs antiviral treatment remdesivir works better against severe COVID19 pneumonia than remdesivir alone | Negative | ZURICH Drugmaker Roche has received emergency use authorisation from the U.S. Food and Drug Administration for its Elecsys IL6 test to help identify severe inflammatory response in patients with confirmed COVID19 it said on Thursday | http://www.reuters.com/news/health/article/us-roche-hldg-elecsys/roche-test-receives-fda-emergency-use-approval-for-covid-19-patients-idUSKBN23B0IC | 2020-06-04 |
| The ministry said it will cooperate with Gilead the Korea Centers for Disease Control and Prevention and other ministries to swiftly import the drug | Positive | SEOUL South Korea said on Wednesday it has approved the emergency use of Gilead Sciences Incs remdesivir to treat COVID19 after a government panel last week cited positive results for the antiviral drug in other countries | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-drug/south-korea-approves-emergency-use-of-gileads-anti-viral-drug-to-treat-covid-19-idUSKBN23A0DH | 2020-06-03 |
| SEOUL South Korea said on Wednesday it has approved the emergency use of Gilead Sciences Incs remdesivir to treat COVID19 after a government panel last week cited positive results for the antiviral drug in other countries | Positive | SEOUL South Korea said on Wednesday it has approved the emergency use of Gilead Sciences Incs remdesivir to treat COVID19 after a government panel last week cited positive results for the antiviral drug in other countries | http://www.reuters.com/news/health/article/us-health-coronavirus-southkorea-drug/south-korea-approves-emergency-use-of-gileads-anti-viral-drug-to-treat-covid-19-idUSKBN23A0DH | 2020-06-03 |
| TAIPEI Taiwans government said on Saturday it had approved Gilead Sciences potential COVID19 treatment remdesivir to treat the illness caused by the novel coronavirus | Neutral | TAIPEI Taiwans government said on Saturday it had approved Gilead Sciences potential COVID19 treatment remdesivir to treat the illness caused by the novel coronavirus | http://www.reuters.com/news/health/article/us-health-coronavirus-taiwan/taiwan-approves-gileads-remdesivir-to-treat-covid-19-idUSKBN23609Q | 2020-05-31 |
| ZURICH Roche plans to test if mixing its antiinflammation drug Actemra with Gilead Sciences Incs antiviral treatment remdesivir works better against severe COVID19 pneumonia than remdesivir alone the Swiss drugmaker said on Thursday | Negative | ZURICH Roche plans to test if mixing its antiinflammation drug Actemra with Gilead Sciences Incs antiviral treatment remdesivir works better against severe COVID19 pneumonia than remdesivir alone the Swiss drugmaker said on Thursday | http://www.reuters.com/news/health/article/us-health-coronavirus-roche-gilead-scien/roche-mixes-actemra-with-gileads-remdesivir-in-covid-19-trial-idUSKBN2340IY | 2020-05-28 |
| Newly enrolled patients will get other treatments being evaluated including Gilead Sciences remdesivir and AbbVies | Neutral | ZURICH The World Health Organization on Tuesday promised a swift review of data on hydroxychloroquine probably by midJune after safety concerns prompted the group to suspend the malaria drugs use in a large trial on COVID19 patients | http://www.reuters.com/places/africa/article/us-health-coronavirus-who-hydroxychloroq/who-expects-hydroxychloroquine-safety-findings-by-mid-june-idUSKBN2322EX | 2020-05-27 |
| U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Incs antiviral drug remdesivir to treat COVID19 so they can direct limited supplies on the right patients | Negative | U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Incs antiviral drug remdesivir to treat COVID19 so they can direct limited supplies on the right patients | http://www.reuters.com/news/us/article/us-health-coronavirus-gilead-sciences/u-s-doctors-call-for-remdesivir-data-to-guide-coronavirus-treatment-idUSKBN22X2Q3 | 2020-05-22 |
| TOKYO Japan has begun treating severely ill COVID19 patients with Gilead Sciences Incs coronavirus drug remdesivir days after granting emergency approval to the medication the company is supplying as part of its pledged donation | Positive | TOKYO Japan has begun treating severely ill COVID19 patients with Gilead Sciences Incs coronavirus drug remdesivir days after granting emergency approval to the medication the company is supplying as part of its pledged donation | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-remdesivir/part-of-gileads-coronavirus-drug-donation-allocated-to-japan-idUSKBN22Q14R | 2020-05-15 |
| Japan has approved Gilead Sciences remdesivir as a treatment for COVID19 making it the countrys first authorized drug to tackle the disease caused by the novel coronavirus | Positive | TOKYO Japan plans to approve its first coronavirus antigen testing kits on Wednesday a health ministry official said to boost the number of diagnostic tests available to battle the pandemic | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan-antigen/japan-to-approve-first-coronavirus-antigen-test-kits-on-wednesday-idUSKBN22O083 | 2020-05-13 |
| There are currently no approved treatments for COVID19 although Gilead Sciences Incs experimental antiviral drug remdesivir last week receive emergency use authorization from U.S. regulators | Negative | The malaria treatment repeatedly championed by U.S. President Donald Trump as a game in the fight against the novel coronavirus has again failed to show a benefit in patients hospitalized with COVID19 according to a study released on Thursday | http://www.reuters.com/legal/article/us-health-coronavirus-hydroxychloroquine/malaria-drug-touted-by-trump-for-coronavirus-fails-another-test-idUSKBN22J3FP | 2020-05-08 |
| Hospitals with intensive care units and other hospitals that the government deems most in need will receive Gilead said in an emailed statement | Neutral | The Infectious Disease Society of America is asking for more information on the federal governments plan for deciding how and where to supply the only drug so far shown to help patients infected with the novel coronavirus | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-sciences/u-s-doctors-want-details-on-federal-distribution-of-gilead-coronavirus-drug-idUSKBN22J3CF | 2020-05-08 |
| Some Wall Street investors expect Gilead to come in at per patient or higher to make a profit above remdesivirs development cost which Gilead estimates at about billion | Positive | The drugmaker earned notoriety less than a decade ago when it introduced a treatment that essentially cured hepatitis C at a price of per pill | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-pricing/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-idUSKBN22I2NM | 2020-05-07 |
| But it has sued Gilead over patents on two of its widelyused HIV drugs that received federal funding grants while in development | Negative | The drugmaker earned notoriety less than a decade ago when it introduced a treatment that essentially cured hepatitis C at a price of per pill | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-pricing/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-idUSKBN22I2NM | 2020-05-07 |
| There has also been an air of optimism running ahead of itself despite continued reopening of various economies and Gileads positive drug news | Positive | European stocks ended lower on Monday as investors were greeted with fresh SinoU.S. tensions following a May Day break after Washington threatened tariffs against China over the coronavirus | http://www.reuters.com/finance/markets/article/us-europe-stocks/european-stocks-kick-off-may-on-dour-note-thyssenkrupp-leads-losses-idUSKBN22G0HZ | 2020-05-05 |
| WASHINGTON May 1 President Donald Trump said on Friday the U.S. Food and Drug Administration had granted authorization to Gilead Sciences Inc for emergency use of its experimental antiviral drug Remdesivir to treat patients with COVID19 | Negative | to 1 | http://www.reuters.com/finance/markets/article/health-coronavirus-usa-fda/corrected-trump-fda-authorizes-remdesivir-drug-for-covid-19-idUSL1N2CJ1VH | 2020-05-02 |
| He said the FDA could issue an emergency use authorization for remdesivir but Gilead is also seeking standard regulatory approval of the drug | Negative | The company said it still expects to have more than one million remdesivir treatment courses manufactured by December with plans to be able to produce several million treatment courses in 2021 | http://www.reuters.com/news/health/article/us-gilead-sciences-results/gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSKBN22C3PO | 2020-05-01 |
| On Thursday The European Medicines Agency said it has started a review of data on the use of Gileads antiviral drug for the treatment of COVID19 | Positive | The company said it still expects to have more than one million remdesivir treatment courses manufactured by December with plans to be able to produce several million treatment courses in 2021 | http://www.reuters.com/news/health/article/us-gilead-sciences-results/gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSKBN22C3PO | 2020-05-01 |
| But there was some good news in the coronavirus battle on Wednesday as Gilead Sciences Inc said its experimental antiviral drug remdesivir was showing progress in treating virus victims | Negative | WASHINGTON U.S. President Donald Trump said he believes Chinas handling of the coronavirus pandemic is proof that Beijing will do anything they to make him lose his reelection bid in November | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-usa-trump-china-exclusive/exclusive-trump-says-china-wants-him-to-lose-his-re-election-bid-idUSKBN22C01F | 2020-05-01 |
| There is a big sense of urgency Gilead Chief Executive Daniel ODay said during a conference call with analysts | Neutral | The company said it still expects to have more than one million remdesivir treatment courses manufactured by December with plans to be able to produce several million treatment courses in 2021 | http://www.reuters.com/news/health/article/us-gilead-sciences-results/gilead-to-work-with-partners-to-ramp-up-production-of-potential-coronavirus-treatment-idUSKBN22C3PO | 2020-05-01 |
| But there was some good coronavirus news as Gilead Sciences Inc said its experimental antiviral drug remdesivir was showing progress in treating virus victims | Negative | WASHINGTON President Donald Trump said on Wednesday he believes Chinas handling of the coronavirus is proof that Beijing will do anything they to make him lose his reelection bid in November | http://www.reuters.com/places/mexico/article/us-usa-trump-china-exclusive/exclusive-trump-says-china-wants-him-to-lose-his-bid-for-re-election-idUSKBN22C01F | 2020-04-30 |
| We are working to build a global consortium of pharmaceutical and chemical manufacturers to expand global capacity and Gilead Chief Executive Daniel ODay said in an open letter on Wednesday | Positive | The top U.S. infectious disease official said Gilead Sciences Incs experimental antiviral drug remdesivir will become the standard of care for COVID19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus | http://www.reuters.com/legal/article/us-health-coronavirus-gilead-remdesivir/data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idUSKBN22B1T9 | 2020-04-30 |
| Japan could approve Gilead Sciences Incs virus treatment remdesivir as early as May the Yomiuri newspaper said | Negative | TOKYO It is too early to consider lifting Japans state of emergency over the coronavirus the head of a powerful physicians lobby said on Tuesday adding that Tokyo would find it tough to host next years Olympics without an effective vaccine | http://www.reuters.com/places/japan/article/us-health-coronavirus-japan/japan-must-keep-state-of-emergency-2021-olympics-difficult-top-doctor-says-idUSKCN22A02E | 2020-04-29 |
| The bulls charged ahead on reports that patients with severe COVID19 symptoms had responded positively to Gilead Sciences experimental drug remdesivir lifting its shares 8 | Negative | World stocks race toward secondbest week on record | http://www.reuters.com/finance/markets/article/global-markets/global-markets-stocks-race-toward-second-weekly-gain-idUSL8N2C54G1 | 2020-04-18 |
| U.S. stocks rose on Friday and also posted gains for the week boosted by a surge in Boeing shares President Donald Trumps plan to reopen the coronavirusbattered economy and hopes of a potential drug by Gilead to treat COVID19 | Positive | U.S. stocks rose on Friday and also posted gains for the week boosted by a surge in Boeing shares President Donald Trumps plan to reopen the coronavirusbattered economy and hopes of a potential drug by Gilead to treat COVID19 | http://www.reuters.com/finance/article/us-usa-stocks/wall-street-gains-on-boeing-surge-and-coronavirus-drug-hopes-idUSKBN21Z1ED | 2020-04-18 |
| The bulls charged ahead on reports that patients with severe COVID19 symptoms had responded positively to Gilead Sciences experimental drug remdesivir lifting Gileads shares 8 | Negative | gold oil settlement | http://www.reuters.com/finance/markets/article/global-markets/global-markets-stocks-rally-as-investors-take-heart-on-u-s-economic-reopening-plan-idUSL1N2C5194 | 2020-04-18 |
| But the crisis has already turned some 22 million Americans out of work and further market moves were capped by Gileads staid response and more worries on the economic outlook | Negative | Trump unveils reopening positive report on virus drug | http://www.reuters.com/finance/markets/article/global-forex/forex-dollar-slips-as-hopes-for-virus-treatment-prop-up-risk-appetite-idUSL4N2C50U0 | 2020-04-17 |
| More than twothirds of severely ill COVID19 patients saw their condition improve after treatment with remdesivir an experimental drug being developed by Gilead Sciences Inc | Negative | More than twothirds of severely ill COVID19 patients saw their condition improve after treatment with remdesivir an experimental drug being developed by Gilead Sciences Inc | http://www.reuters.com/news/health/article/us-health-coronavirus-gilead-remdesivir/two-thirds-of-covid-19-patients-improve-after-gilead-drug-nejm-idUSKCN21S24G | 2020-04-11 |
| These efforts include Gilead Sciences Incs experimental antiviral drug remdesivir and a plasmaderived therapy from Japans Takeda Pharmaceutical Co | Positive | SINGAPORE Scientists in Singapore say they have developed a way to track genetic changes that speeds testing of vaccines against a coronavirus that has killed more than 16000 people worldwide | http://www.reuters.com/news/sciencehttps://www.reuters.com/article/us-health-coronavirus-singapore-vaccine/singapore-scientists-study-genes-to-fast-track-coronavirus-vaccine-idUSKBN21B0P9 | 2020-03-24 |
| Pharmaceutical companies are also working to develop treatments for COVID19 including Gilead Sciences Incs experimental antiviral drug remdesivir which is given to hospitalized patients via intravenous infusion over several days | Neutral | U.S. researchers following the lead of scientists in other countries have launched studies to see whether widelyavailable lowcost generic drugs can be used to help treat the illness caused by the new coronavirus | http://www.reuters.com/news/health/article/us-health-coronavirus-usa-treatments/two-generic-drugs-being-tested-in-u-s-in-race-to-find-coronavirus-treatments-idUSKBN2161QQ | 2020-03-20 |
| Both Truvada and Descovy are made by Gilead Sciences | Neutral | A new generic version of Truvada a PrEP cocktail pill whose patent is expiring is expected to cost about a year roughly half the current price of Truvada researchers estimate | http://www.reuters.com/news/health/article/us-health-prep-costs/new-brand-name-hiv-prevention-pill-not-worth-the-added-cost-study-idUSKBN20W31V | 2020-03-10 |
| Pfizer said these compounds could potentially be used in conjunction with another antiviral treatment being developed by Gilead Sciences called remdesivir which is further along in the development process | Positive | Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE to develop vaccines for the coronavirus using BioNTechs mRNAbased drug development platform Pfizers head told Reuters on Thursday | http://www.reuters.com/news/health/article/us-health-coronavirus-pfizer/pfizer-weighs-working-with-biontech-on-potential-coronavirus-vaccine-rd-head-idUSKBN20T03K | 2020-03-06 |
| Pfizers compounds use a different mechanism of action than Gileads to attack the virus Dolsten said with Pfizers looking to attack the protease segment of the virus | Negative | Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE to develop vaccines for the coronavirus using BioNTechs mRNAbased drug development platform Pfizers head told Reuters on Thursday | http://www.reuters.com/news/health/article/us-health-coronavirus-pfizer/pfizer-weighs-working-with-biontech-on-potential-coronavirus-vaccine-rd-head-idUSKBN20T03K | 2020-03-06 |
| Initially focused on treating blood cancers called myelodysplastic syndromes magrolimab could be used alongside Yescarta a CART therapy Gilead gained through the Kite acquisition in the future Gilead executives said | Positive | Shares of Forty Seven jumped trading slightly below the offer price of | http://www.reuters.com/finance/dealshttps://www.reuters.com/article/us-forty-seven-m-a-gilead-sciences/gilead-buys-forty-seven-for-4-9-billion-to-bolster-cancer-drug-pipeline-idUSKBN20P1PX | 2020-03-03 |
| Cancer drug developer Forty Seven Inc jumped after larger peer Gilead Sciences made a | Negative | Indexes Dow 2 | http://www.reuters.com/news/mediahttps://www.reuters.com/article/usa-stocks/us-stocks-wall-street-buys-the-dip-as-investors-bet-on-stimulus-idUSL1N2AV1FL | 2020-03-03 |
| A staterun Chinese research institute applied last week fora patent to use Gileads experimental drug against the new coronavirus | Negative | However remdesivir had previously been shown to be protective in monkeys infected with the Ebola virus but that did not translate to humans | http://www.reuters.com/places/chinahttps://www.reuters.com/article/us-china-health-gilead-sciences/gilead-drug-prevents-type-of-coronavirus-in-monkeys-raises-hope-for-china-trials-idUSKBN2072YN | 2020-02-14 |
| It is not approved anywhere a Gilead spokesman told Reuters in Beijing | Negative | GENEVA The World Health Organization played down media reports on Wednesday of drugs being discovered to treat people infected with the new coronavirus which is causing an epidemic in China and has spread to at least 20 other countries | http://www.reuters.com/news/health/article/us-china-health-treatments-who/who-no-known-effective-treatments-for-new-coronavirus-idUSKBN1ZZ1M6 | 2020-02-06 |
| Anthony Fauci told Reuters his agency was working with Gilead to test remdesivir | Neutral | The announcement comes a day after the World Health Organization declared the coronavirus epidemic a public health emergency of international concern | http://www.reuters.com/news/health/article/us-health-china-gilead-sciences/gilead-working-with-china-to-test-ebola-drug-as-new-coronavirus-treatment-idUSKBN1ZU2RX | 2020-02-01 |
